Axon Enterprise, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +15

Should Axon Enterprise Stock be in Your Portfolio Pre-Q3 Earnings?

AI integration Acquisition Company update AI-generated analysis

πŸ“… Axon Enterprise is set to release Q3 2026 earnings on Nov. 5 with consensus estimates of $1.90 EPS and $931.1M revenue.

πŸ“‰ Earnings estimates have decreased 2.1% over the past 60 days, and the company has missed estimates in three of the last four quarters.

πŸš€ The Connected Devices segment is expected to grow 28.6% YoY driven by TASER 10 demand and Axon Body 4 adoption.

πŸ’» Software & Services revenue is projected to increase 36.7% YoY fueled by premium software adoption and platform momentum.

🀝 The company acquired Carbyne in February 2026 to integrate advanced cloud-native 911 technology into its Axon ecosystem.

⚠️ Rising operating costs, integration expenses, and stock-based compensation are expected to weigh on the bottom line.

πŸ“ˆ AXON shares have gained 9.4% in six months, outperforming the Zacks Aerospace - Defense Equipment industry which declined 9.7%.

πŸ’° The stock trades at a forward P/E of 41.89X, significantly higher than the industry average of 32.34X and peer Teledyne's 24.36X.

πŸ›‘οΈ Strong demand for TASER devices and growth in the counter-drone market position the company favorably ahead of earnings.

πŸ“‰ High valuation and elevated costs warrant a cautious approach for investors waiting for Q3 results.

Bullish Signals
  • Axon Enterprise is expected to deliver substantial year-over-year revenue growth, with Connected Devices segment revenues pegged at $521 million (28.6% increase) and Software & Services at $417 million (36.7% increase).
  • The company has successfully integrated Carbyne's cloud-native 911 technology to create Axon 911, expanding its product offerings in the public safety sector.
  • AXON shares have gained 9.4% over the past six months, significantly outperforming the Zacks Aerospace - Defense Equipment industry which saw a 9.7% decline.
  • Strong market demand for TASER 10 products and continued adoption of the Axon Body 4 camera are driving solid performance in the Connected Devices segment.
  • The company maintains a strong presence in the counter-drone space, contributing significantly to segment growth and diversifying its revenue streams.
Risk Factors
  • The Zacks Consensus Estimate for earnings has decreased 2.1% over the past 60 days, indicating weakening analyst confidence or deteriorating expectations.
  • Axon Enterprise missed earnings estimates in three of the last four quarters with an average negative surprise of 0.8%, suggesting a history of underperformance relative to consensus.
  • Rising operating costs, high integration expenses, and stock-based compensation are expected to weigh on the company's bottom line in the upcoming quarter.
  • The stock is trading at a forward P/E ratio of 41.89X, which is much higher than the industry average of 32.34X and peer Teledyne Technologies' 24.36X, creating valuation risk.
  • Elevated valuation makes the stock vulnerable to further pullbacks if market sentiment sours or if Q3 results fail to meet high expectations.
Full Analysis
Axon Enterprise is scheduled to report its third-quarter 2026 earnings results on November 5, following market close. Analysts currently project earnings of $1.90 per share on revenues of $931.1 million, representing a significant year-over-year increase in both metrics. However, the consensus estimate for quarterly earnings has decreased by 2.1% over the past 60 days, while the company's historical track record shows it missed estimates three times in the trailing four quarters with an average negative surprise of 0.8%. The company expects strong performance from its Connected Devices segment, driven by demand for TASER 10 products and higher cartridge revenues, alongside continued adoption of the Axon Body 4 camera and counter-drone solutions. The Software & Services segment is anticipated to grow due to increased user adoption of premium software and momentum in platforms like Axon Evidence and Axon 911. Revenue estimates for these segments are pegged at $521 million and $417 million respectively, indicating substantial year-over-year growth. Strategic initiatives, including the February 2026 acquisition of Carbyne to enhance its Axon 911 solution, are expected to boost top-line revenue. Despite these positives, analysts warn that rising operating costs, integration expenses, and stock-based compensation could weigh on the company's bottom line. The stock is trading at a forward P/E ratio of 41.89X, which is notably higher than its industry average and peers like Teledyne Technologies, raising concerns about valuation vulnerability if market sentiment shifts.